within Pharmacolibrary.Drugs.ATC.J;

model J04AM06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.000145,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.052,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 900
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AM06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This combination drug is used for the treatment of active tuberculosis infection and is composed of rifampicin, pyrazinamide, ethambutol, and isoniazid. It is an essential, approved regimen in first-line tuberculosis therapy recommended by the WHO and many national tuberculosis programs. It targets Mycobacterium tuberculosis through multiple mechanisms: rifampicin inhibits RNA synthesis, isoniazid inhibits mycolic acid synthesis, pyrazinamide disrupts membrane energetics, and ethambutol interferes with cell wall synthesis.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with pulmonary tuberculosis receiving fixed-dose combination tablets under directly observed therapy; mixed male and female, mean age around 38 years.</p><h4>References</h4><ol><li><p>Sibley, L, et al., &amp; Sharpe, S (2022). Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of . <i>Pharmaceutics</i> 14(12) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14122666\">10.3390/pharmaceutics14122666</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36559163/\">https://pubmed.ncbi.nlm.nih.gov/36559163</a></p></li><li><p>Xu, J, et al., &amp; Lu, Y (2013). Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers. <i>Clinical therapeutics</i> 35(2) 161–168. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2013.01.003\">10.1016/j.clinthera.2013.01.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23410999/\">https://pubmed.ncbi.nlm.nih.gov/23410999</a></p></li><li><p>Chen, C, et al., &amp; Simonsson, US (2016). Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 93 319–333. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2016.07.017\">10.1016/j.ejps.2016.07.017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27473307/\">https://pubmed.ncbi.nlm.nih.gov/27473307</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AM06;
